Two patients with primary hyperparathyroidism had hyperuricemia due to the decrease in urate clearance. In analysis by 4-component model system, the tubular secretion of urate commonly decreased without changes in either filtered urate or presecretory reabsorption of urate. Both patients had a reduction of urea clearance, and both parathyroidectomy in the former case and intravenous infusion of saline in the latter case could reduce the serum urate level associated with the increase in the ratio of urate clearance to creatinine clearance. It is of interest that the former case with a higher serum urate level had a relatively higher postsecretory reabsorption, even with the decrease in tubular secretion of urate. However, the latter patient with a lower serum urate level had a decrease in postsecretory reabsorption of urate in pro portion to the decrease in tubular secretion. These results suggest that in hyperuricemia patients with primary hyperparathyroidism, the reduction of tubular urate secretion via hypoperfusion of the capillary network is typically present, however, the severity of the hyperuricemia might be dependent on the dysfunction of the postsecretory reabsorption of urate. (Internal Medicine 31: 807-811, 1992) 
Introduction
It is well known that hyperuricemia is often associated with primary hyperparathyroidism (1) (2) (3) (4) (5) . However, the mechanism of hyperuricemia associated with primary hyperparathyroidism remains unclear. A recent report (6) suggested that hyperuricemia in primary hyperparathyroidism patients is the result of decreased urinary excretion of urate. In their patients, urate clearance returned to normal after the removal of parathyroid adenomas, suggesting that the renal urate handling in hyperparathyroidism might be impaired. In contrast, other reports (7) have shown that the serum urate in patients with primary hyperparathyroidism does not correlate with urate clearance. Therefore, to elucidate the mechanisms of hyperuricemia in primary hyperparathyroidism patients, it is necessary to study the renal handling of urate in these patients according to the 4-component model (8) . However, few reports discuss the precise renal handling of urate in hyperuricemic patients with primary hyperparathyroidism. Therefore, in order to study the mechanism of hyperuricemia in primary hyperparathyroidism from the viewpoint of the renal handling of urate, we examined the urate metabolism of two hyperuricemic patients with hyperparathyroidism based on the pharmacological estimation using pyrazina mide, a urate secretion inhibitor (9), and probenecid, a urate postreabsorption inhibitor (10, ll findings of blood chemistry were as follows: sodium 137mEq/l, potassium 5.1mEq/l, chloride 105mEq/l, calcium 13.2mg/dl, inorganic phosphate 1.8 mg/dl, urea nitrogen 34mg/dl, creatinine 1.6mg/dl, triglycerides 91 mg/dl, chloesterol 233 mg/dl and fasting blood sugar lOOmg/dl. Serum protein was 6.7g/dl with a normal electrophoretic and immunoelectrophoretic pattern. He had a renal stone. A liver function test, and roent genogram of the chest, spine, and long bones were nor mal. Morning urinary pH remained less than 6.0. Blood pH was 7.43 and PaCO2 was 36.6mmHg. Creatinine clearance was 57.4 ± 5.4ml/min/1.73m2 body surface area (n = 4). C terminal-HSPTH was 2.5 jig/ml and HS middle molecule PTH was 4092.7pg/dl as measured by PTH Kit-Yamasa (Yamasa, Chiba, Japan). Tubular reabsorption of inorganic phosphate was 65.5%. Urea clearance was 16.1ml/mim/1.73m2 body surface area (normal subjects, n = 5: 60.5 ± 7.3ml/min/1.73m2 body surface area). There was no evidence for renal tubular acidosis or any other tubular abnormalities. Careful examination did not reveal any sign of malignancy or bone pathology. We diagnosed this patient as hyper uricemia associated with primary hyperparathyroidism.
Case2
A 72-year-old female was admitted on April 24, 1990 for investigation of both hypercalcemia and hypopho sphatemia. Physical examination revealed a normal woman. On admission, she was found to have hyper uricemia (8.2mg/dl) as measured by a uricase assay. Urinalysis revealed neither proteinuria nor aminoaciduria. Other findings of blood chemistry were as follows: sodium 141mEq/l, potassium 5.2mEq/l, cloride 103mEq/l, calcium 12.3 mg/dl, inorganic phosphate 2.5 mg/dl, urea nitrogen 31mg/dl, creatinine l.lmg/dl, triglycerides 200 mg/dl and cholesterol 260 mg/dl. Serum protein was 6.8g/dl with a normal electrophoretic and immuno electrophoretic pattern. A liver function test, and roent genogram of the chest, spine, and long bones were all normal. She had no history of a renal stone. Morning urinary pH remained less than 6.0. Blood pH was 7.39 and PaCO2 was 43.9mmHg. Creatinine clearance was 58.8 ± 1.97ml/min/1.73m2 body surface area (n = 4). C terminal HSPTH was 3.6 ng/ml and HS-middle molecule PTH was 7,300 pg/ml. Tubular reabsorption of inorganic phosphate was 72%. Urea clearance was 33.1ml/min/ 1.73m2 body surface area. There was no evidence for renal tubular acidosis or any other tubular abnormalities.
Careful examination did not reveal any sign of malignancy or bone pathology. We diagnosed this patient as hyper uricemia with primary hyperparathyroidism.
Methods
Throughout the study, the patients were maintained on a regular diet. Serum urate (Sur) and urinary urate concentrations were determined by a uricase assay (12) and serum and urinary creatinine levels were determined by an enzymatic method. A 7-day period was allowed between tests to avoid pharmacological interference. The study started in the morning after an overnight fast; breakfast was omitted. Bladder catheterization was avoided by oral hydration with 500ml of water before and during each study. All urine specimens exceeded 200ml in volume. Pyrazinamide and probenecid tests were performed according to the methods of Steele and Rieselbach (13) and Barrientos et al (14), respectively. Each test consisted of two phases: one before and one after drug administration (pyrazinamide 3 g orally in a single dose; probenecid 2g orally in a single dose). In each study, both phases consisted of at least three 30-min clearance periods. A venous blood sample was drawn in the middle of each clearance period. The first clearance period started after 60 min of drug administration. Endogenous creatinine clearance (Ccr) was used throughout the studies to estimate the glo merular filtration rate (GFR). It is well known that it takes 1 hour to show the effect of pyrazinamide and probenecid and 1.5 hour to achieve the maximum effect after administration of these drugs (15). Actually, the majority of subjects (10, ll, 15) exhibit minimum urico suria following pyrazinamide and maximum uricosuria following probenecid in the second clearance period after drug administration. Presecretory reabsorption of urate was calculated as filtered urate (GFR x Sur) minus the minimum amuont of uratu excreted after pyrazina mide administration; this was expressed as the percent age of filtered urate. Tubular secretion of urate was calculated as the maximum urate excretion after pro benecid administration and was expressed in terms of percentage of filtered urate. Postsecretory reabsorption of urate was calculated as the difference between tubular secretion of urate and the amount of urate excreted in the basal periods; this was expressed in terms of percent age of secreted urate. In aged-matched control subjects (n=5), presecretory reabsorption was 99.3 ±0.3%, tubular secretion was 40.4 ± 4.5%, and postsecretory reabsorption was 76.8 ± 5.6%. These levels are similar to those reported by Puig et al (16) .
Results

1) Urate metabolism
In case 1, the serum urate value was 9.3 ± 1.2mg/dl (n = 4), urinary urate excretion was 321mg/day, urate clearance (Cur) was 2.80 ± 0.57ml/min/1.73m2 body surface area (n = 4) and the ratio of urate clearance to creatinine clearance (Cur/Ccr) was 4.86 ± 0.56% (n = 4). In case 2, the serum urate value was 7.6±0.4mg/dl (n = 4), urinary urate excretion was 394mg/day, urate clearance was 3.77 ± 1.27ml/min/1.73m2 body surface area (n=4) and Cur/Ccr was 7.70±0.26% (n=4). Normal values of parameters (mean ± SD) taken from 5 normal adults 2) Tubular phases of urate excretion Table 2 . Both patients had a normal presecretory reabsorption, how ever, their tubular secretion was decreased. Case 1 had a normal postsecretory reabsorption but case 2 had a decreased postsecretory reabsorption.
3) Effects of adenomectomy and hydration on urate excretio n In case 1, after serum C terminal-HSPTH level re turned to the normal level at 0.9ng/ml by parathyroi dectomy, the serum urate decreased to 7.0mg/dl and Cur/Ccr increased to ll.3%. In case 2, after intravenous infusion of saline at 500ml/30min, Sur was reduced from 7.4mg/dl to 7.1 mg/dl and Cur/Ccr was increased from 7.8% to ll.1%.
Discussion
In the present study, we analyzed the urate metabolism of two patients with hyperuricemia and primary hyper parathyroidism based on the pharmacological evaluation.
There are three mechanisms which may lead to an in crease in serum urate: endogenous overproduction, de creased urinary excretion, or a combination of both (8). The normal urate excretion in the present cases could negates the possibility of endogenous urate over production. On the other hand, the decrease in Cur The results of both cases showed that the tubular se cretion of urate was commonly reduced without changes in either the filtration of urate or presecretory reab sorption of urate. The possible causes which could affect the urate tubular secretion in the hyperparathyroidism patients are as follows: 1) a direct action of parathyroid hormone on the tubular transport of urate, 2) volume contraction, because the other causes for the decrease in tubular secretion of urate, such as hypertension, drugs, and ketosis could be denied. It is difficult to identify which mechanism is responsible for the hyperuricemia in hyperparathyroidism patients. Indeed, a direct action of PTH on the tubular transport of urate might also be advocated since PTH is known to modulate the tubular reabsorption of several molecules and to stimulate C AMP production in the proximal tuble, but plasma urate does not change in normal subjects after PTH injection (17) and no correlations were found between plasma urate and PTH in a hyperparathyroidism group (6). In the present cases, while PTH activity was higher in ease 2 than that in case 1, the serum urate level was higher in case 1 than that in case 2, thereby, the overactivity of PTH was unlikely the main cause of hyperuricemia in the present cases. Volume contraction secondary to dehydration, which may result from hypercalcemia, is well known to decrease urate clearance and to raise serum urate, probably by decreasing the urate secretion (18). It is important to check whether the present cases had volume contraction or not. The urea clearance is a good index of volume depletion (19). In both of the present cases, the urea clearance decreased in com parison with control subjects, which might suggest that volume contraction secondary to dehydration from hypercalcemia might exist in the present cases. In case 2, intravenous infusion of saline reduced the serum urate level associated with the increase in Cur/Ccr, which finding might directly support the above possibility.
In addition, in case 1, adenomectomy reduced the serum urate level with an increase in Cur/Ccr; this phenomenon was similar to the effect of intravenous hydration. There fore, the hypothesis that hypoperfusion of the peri tubular capillary network due to volume contraction could decrease the tubular secretion of urate was in favor of the hyperuricemia in our data and this finding might be the reverse pathophysiology of the diabetic renal hypouricemia descirbed by Shichiri et al (10) . These cases of hyperuricemia with hyperparathyroidism have been reversible by means of either adenomectomy or intravenous hydration. It has been previously reported that the mean serum urate level tends to be greater and the mean fractional excretion lesser with a history of urolithiasis (6, 20) . Case 1 with urolithiasis had the higher serum urate and the lesser urate excretion, compared to case 2 withtout urolithiasis, which is well compatible with the above reports. The severity of the hyperuricemia in the present cases might be related to the difference of function of the postsecretory reabsorption of urate among cases. The function of postsecretory reabsorption of urate is dependent on the amount of urate tubular secretion.
In the case of hypouricemia caused by hypersecretion (10, 21), probenecid or benzbromarone-induced block on postsecretory reabsorption could markedly increase Cur compared to control, which indicates that post secretory reabsorption could be dependent on tubular secretion. In contrast, it is reasonable to assume that the decrease in postsecretory reabsorption in case 2 was accompanied by a decrease in tubular secretion of urate, as the postsecretory reabsorption of urate might be attenuated due to the reduction of urate secretion. However, the postsecretory reabsorption of urate in case 1 was not altered even when the tubular urate secretion was reduced; this may have elevated the serum urate in case 1 via dysfuction of postsecretory reab sorption which was larger than in case 2. These results suggest that the common pathophysiology to reveal hyperuricemia in the present cases in mainly a result of the reduction of tubular urate secretion mediated by volume depletion-induced hypoperfusion of the capillary network, but the severity of hyperuricemia might be related to the exsistence of urolithiasis and the dysfunc tion of postsecretory reabsorption of urate. Kageyama N. A direct colorimetric determination of uric acid in serum and urine with a uricase-catalase system. Clin Chim Acta
